"Th1 Cells" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subset of helper-inducer T-lymphocytes which synthesize and secrete INTERLEUKIN-2; INTERFERON-GAMMA; and INTERLEUKIN-12. Due to their ability to kill antigen-presenting cells and their lymphokine-mediated effector activity, Th1 cells are associated with vigorous delayed-type hypersensitivity reactions.
| Descriptor ID |
D018417
|
| MeSH Number(s) |
A11.118.637.555.567.550.500.400.900 A11.118.637.555.567.569.200.400.900 A11.118.637.555.567.569.500.400.900 A15.145.229.637.555.567.550.500.400.500 A15.145.229.637.555.567.569.200.400.500 A15.145.229.637.555.567.569.500.400.500 A15.382.490.555.567.550.500.400.900 A15.382.490.555.567.569.200.400.900 A15.382.490.555.567.569.500.400.900
|
| Concept/Terms |
Th1 Cells- Th1 Cells
- Cell, Th1
- Cells, Th1
- Th1 Cell
- TH-1 Cells
- Cell, TH-1
- Cells, TH-1
- TH 1 Cells
- TH-1 Cell
- T Helper 1 Cells
- Type 1 Helper T Cells
|
Below are MeSH descriptors whose meaning is more general than "Th1 Cells".
- Anatomy [A]
- Cells [A11]
- Blood Cells [A11.118]
- Leukocytes [A11.118.637]
- Leukocytes, Mononuclear [A11.118.637.555]
- Lymphocytes [A11.118.637.555.567]
- Lymphocyte Subsets [A11.118.637.555.567.550]
- T-Lymphocyte Subsets [A11.118.637.555.567.550.500]
- T-Lymphocytes, Helper-Inducer [A11.118.637.555.567.550.500.400]
- Th1 Cells [A11.118.637.555.567.550.500.400.900]
- T-Lymphocytes [A11.118.637.555.567.569]
- CD4-Positive T-Lymphocytes [A11.118.637.555.567.569.200]
- T-Lymphocytes, Helper-Inducer [A11.118.637.555.567.569.200.400]
- Th1 Cells [A11.118.637.555.567.569.200.400.900]
- T-Lymphocyte Subsets [A11.118.637.555.567.569.500]
- T-Lymphocytes, Helper-Inducer [A11.118.637.555.567.569.500.400]
- Th1 Cells [A11.118.637.555.567.569.500.400.900]
- Hemic and Immune Systems [A15]
- Blood [A15.145]
- Blood Cells [A15.145.229]
- Leukocytes [A15.145.229.637]
- Leukocytes, Mononuclear [A15.145.229.637.555]
- Lymphocytes [A15.145.229.637.555.567]
- Lymphocyte Subsets [A15.145.229.637.555.567.550]
- T-Lymphocyte Subsets [A15.145.229.637.555.567.550.500]
- T-Lymphocytes, Helper-Inducer [A15.145.229.637.555.567.550.500.400]
- Th1 Cells [A15.145.229.637.555.567.550.500.400.500]
- T-Lymphocytes [A15.145.229.637.555.567.569]
- CD4-Positive T-Lymphocytes [A15.145.229.637.555.567.569.200]
- T-Lymphocytes, Helper-Inducer [A15.145.229.637.555.567.569.200.400]
- Th1 Cells [A15.145.229.637.555.567.569.200.400.500]
- T-Lymphocyte Subsets [A15.145.229.637.555.567.569.500]
- T-Lymphocytes, Helper-Inducer [A15.145.229.637.555.567.569.500.400]
- Th1 Cells [A15.145.229.637.555.567.569.500.400.500]
- Immune System [A15.382]
- Leukocytes [A15.382.490]
- Leukocytes, Mononuclear [A15.382.490.555]
- Lymphocytes [A15.382.490.555.567]
- Lymphocyte Subsets [A15.382.490.555.567.550]
- T-Lymphocyte Subsets [A15.382.490.555.567.550.500]
- T-Lymphocytes, Helper-Inducer [A15.382.490.555.567.550.500.400]
- Th1 Cells [A15.382.490.555.567.550.500.400.900]
- T-Lymphocytes [A15.382.490.555.567.569]
- CD4-Positive T-Lymphocytes [A15.382.490.555.567.569.200]
- T-Lymphocytes, Helper-Inducer [A15.382.490.555.567.569.200.400]
- Th1 Cells [A15.382.490.555.567.569.200.400.900]
- T-Lymphocyte Subsets [A15.382.490.555.567.569.500]
- T-Lymphocytes, Helper-Inducer [A15.382.490.555.567.569.500.400]
- Th1 Cells [A15.382.490.555.567.569.500.400.900]
Below are MeSH descriptors whose meaning is more specific than "Th1 Cells".
This graph shows the total number of publications written about "Th1 Cells" by people in this website by year, and whether "Th1 Cells" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 2 | 4 | 6 |
| 1998 | 0 | 2 | 2 |
| 1999 | 1 | 2 | 3 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 3 | 3 |
| 2002 | 2 | 4 | 6 |
| 2003 | 3 | 1 | 4 |
| 2004 | 2 | 3 | 5 |
| 2005 | 1 | 4 | 5 |
| 2006 | 3 | 5 | 8 |
| 2007 | 5 | 3 | 8 |
| 2008 | 3 | 4 | 7 |
| 2009 | 6 | 4 | 10 |
| 2010 | 4 | 5 | 9 |
| 2011 | 3 | 2 | 5 |
| 2012 | 3 | 3 | 6 |
| 2013 | 2 | 4 | 6 |
| 2014 | 3 | 7 | 10 |
| 2015 | 1 | 2 | 3 |
| 2016 | 1 | 2 | 3 |
| 2017 | 2 | 2 | 4 |
| 2018 | 4 | 3 | 7 |
| 2019 | 2 | 4 | 6 |
| 2020 | 0 | 3 | 3 |
| 2021 | 5 | 0 | 5 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Th1 Cells" by people in Profiles.
-
An ocular Th1 immune response promotes corneal nerve damage independently of the development of corneal epitheliopathy. J Neuroinflammation. 2023 May 22; 20(1):120.
-
Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice. Front Immunol. 2022; 13:800295.
-
CD11c participates in triggering acute graft-versus-host disease during bone marrow transplantation. Immunology. 2021 09; 164(1):148-160.
-
Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. Leukemia. 2021 11; 35(11):3163-3175.
-
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. J Immunother Cancer. 2021 05; 9(5).
-
Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect. Cancer Immunol Res. 2021 04; 9(4):365-370.
-
The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy. Front Immunol. 2021; 12:625667.
-
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020 12 10; 383(24):2320-2332.
-
MHC class I and II peptide homology regulates the cellular immune response. FASEB J. 2020 06; 34(6):8082-8101.
-
Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia. Blood Adv. 2020 Jan 28; 4(2):387-397.